Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma: Therapeutic and Clinical Implications.
Aurelia LamanuzziIlaria SaltarellaAntonia RealeAssunta MelaccioAntonio Giovanni SolimandoConcetta AltamuraGrazia TammaClelia Tiziana StorlazziDoron TolomeoVanessa DesantisMaria Addolorata MariggiòJean Francois DesaphyAndrew SpencerAngelo VaccaBenedetta ApollonioMaria Antonia FrassanitoPublished in: Biomedicines (2023)
Extracellular vesicles (EVs) have emerged as important players in cell-to-cell communication within the bone marrow (BM) of multiple myeloma (MM) patients, where they mediate several tumor-associated processes. Here, we investigate the contribution of fibroblasts-derived EVs (FBEVs) in supporting BM angiogenesis. We demonstrate that FBEVs' cargo contains several angiogenic cytokines (i.e., VEGF, HGF, and ANG-1) that promote an early over-angiogenic effect independent from EVs uptake. Interestingly, co-culture of endothelial cells from MM patients (MMECs) with FBEVs for 1 or 6 h activates the VEGF/VEGFR2, HGF/HGFR, and ANG-1/Tie2 axis, as well as the mTORC2 and Wnt/β-catenin pathways, suggesting that the early over-angiogenic effect is a cytokine-mediated process. FBEVs internalization occurs after longer exposure of MMECs to FBEVs (24 h) and induces a late over-angiogenic effect by increasing MMECs migration, chemotaxis, metalloproteases release, and capillarogenesis. FBEVs uptake activates mTORC1, MAPK, SRC, and STAT pathways that promote the release of pro-angiogenic cytokines, further supporting the pro-angiogenic milieu. Overall, our results demonstrate that FBEVs foster MM angiogenesis through dual time-related uptake-independent and uptake-dependent mechanisms that activate different intracellular pathways and transcriptional programs, providing the rationale for designing novel anti-angiogenic strategies.
Keyphrases
- endothelial cells
- bone marrow
- vascular endothelial growth factor
- end stage renal disease
- multiple myeloma
- chronic kidney disease
- newly diagnosed
- ejection fraction
- cell proliferation
- gene expression
- peritoneal dialysis
- mesenchymal stem cells
- prognostic factors
- stem cells
- oxidative stress
- angiotensin ii
- signaling pathway
- clinical trial
- transcription factor
- cell therapy
- high glucose
- pi k akt
- public health
- heat stress